Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 8,143 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period 1 Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

NCT03689972
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Aronia on Inflammation and the Gut Microbiome

NCT04128839
View directory record Official record
Conditions
Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions
Aronia berry juice, Sham comparator
Dietary Supplement · Other
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional

Feasibility of Delivering a Complex Behavioral Intervention for Young Adults With Diabetes Via Telehealth

NCT03333772
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
REAL-T Intervention
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

NCT01769677
View directory record Official record
Conditions
Pain
Interventions
90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Nov 10, 2026, 5:46 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457
View directory record Official record
Conditions
Episodic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 10, 2026, 5:46 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

NCT04122001
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
Interventions
Active, in-person HD-tDCS or active remote tDCS, Sham, Word List Learning Intervention (WordLLI)
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 4 Interventional Results available

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

NCT01164475
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Duarte, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeting Worry to Improve Sleep

NCT03684057
View directory record Official record
Conditions
Anxiety, Sleep Disturbance
Interventions
App-Delivered Mindfulness Training (MT)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2

NCT02556177
View directory record Official record
Conditions
Concussion, Traumatic Brain Injury
Interventions
MRI
Procedure
Lead sponsor
GE Healthcare
Industry
Eligibility
15 Years to 50 Years
Enrollment
477 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

NCT02283788
View directory record Official record
Conditions
Epilepsy
Interventions
BIA 2-093, Moxifloxacin, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 2 Interventional

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

NCT05035641
View directory record Official record
Conditions
Renal Anemia
Interventions
AND017, Placebo
Drug
Lead sponsor
Kind Pharmaceuticals LLC
Industry
Eligibility
20 Years to 74 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 1 Interventional

Treatment -Resistant Neovascular Age-Related Macular Degeneration

NCT02332941
View directory record Official record
Conditions
Macular Degeneration
Interventions
Rituximab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
41 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

NCT04465396
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Teduglutide, Syringe Injection, Pen injector
Drug · Device
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 3 Interventional Results available

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

NCT01962441
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Riverside, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional

A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability

NCT02682654
View directory record Official record
Conditions
Joint Instability
Interventions
Dr. Scholl's Prototype Ankle Brace, Dr. Scholl's Prototype Knee Brace
Device
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Nov 10, 2026, 5:46 PM EST
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

NCT01575054
View directory record Official record
Conditions
Muscle Spasticity
Interventions
botulinum toxin Type A, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Downey, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Intermediate Wheatgrass Products and Gut Health

NCT07773441
View directory record Official record
Conditions
Gut Health, Gastrointestinal Symptoms, Gut Microbiome, Dietary Fiber
Interventions
Intermediate Wheatgrass-Based Products, Whole Wheat-Based Products
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Results available

Resistance Exercise and Knee Osteoarthritis Pain, Functional Impairment and Cartilage Turnover

NCT01245283
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
normal activities and clinical care, Concentric Focused Resistance Exercise, Eccentric Focused Resistance Exercise
Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Nov 10, 2026, 5:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Validation of Alcohol Level Identification Using DRIVESC

NCT07282405
View directory record Official record
Conditions
Driving Impaired
Interventions
DRIVESC, Alcohol
Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 10, 2026, 5:46 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 10, 2026, 5:46 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 10, 2026, 5:46 PM EST
Completed No phase listed Observational

Sound Levels in the Pediatric Cardiac Critical Care Unit and Their Correlation With Sedation Administration, Delirium Scores and Patient Heart Rate

NCT04777695
View directory record Official record
Conditions
Noise Exposure, Sedative Withdrawal Delirium, Sedative Toxicity
Interventions
Decibel Monitor
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 22 Years
Enrollment
64 participants
Timeline
2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Nov 10, 2026, 5:46 PM EST